Want to join the conversation?
$BIIB 2Q15 Q&A: Kasimov of JPMorgan asked a question about aducanumab titration. George answered that BIIB haven’t released the specific details on how the up titration is going to work. All of the patients will undergo that process as they get to their final dose in the study. Company will have more clarity once it begins enrolling patients.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.